Mayne Pharma Group Limited

OTCPK:MAYN.F Stock Report

Market Cap: US$236.3m

Mayne Pharma Group Valuation

Is MAYN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MAYN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MAYN.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MAYN.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MAYN.F?

Key metric: As MAYN.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MAYN.F. This is calculated by dividing MAYN.F's market cap by their current revenue.
What is MAYN.F's PS Ratio?
PS Ratio0.9x
SalesAU$388.40m
Market CapAU$363.54m

Price to Sales Ratio vs Peers

How does MAYN.F's PS Ratio compare to its peers?

The above table shows the PS ratio for MAYN.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
NKTR Nektar Therapeutics
2.1x11.8%US$193.7m
BTMD biote
1x16.2%US$217.3m
MDWD MediWound
8.8x38.6%US$177.8m
PROC Procaps Group
0.3xn/aUS$103.8m
MAYN.F Mayne Pharma Group
0.9x11.3%US$363.5m

Price-To-Sales vs Peers: MAYN.F is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does MAYN.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

74 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.8x10.1%
MAYN.F Mayne Pharma Group
 0.9x11.3%US$236.25m
OGN Organon
0.6x-0.06%US$3.94b
PRGO Perrigo
0.9x3.4%US$3.83b
MAYN.F 0.9xIndustry Avg. 2.8xNo. of Companies73PS048121620+
74 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.8x23.7%
MAYN.F Mayne Pharma Group
 0.9x110.0%US$236.25m
No more companies

Price-To-Sales vs Industry: MAYN.F is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Pharmaceuticals industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is MAYN.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MAYN.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MAYN.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MAYN.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$4.01
0%
2.6%US$4.12US$3.90n/a2
Nov ’25US$3.00
US$4.12
+37.4%
2.6%US$4.23US$4.01n/a2
Oct ’25n/a
US$4.12
0%
2.6%US$4.23US$4.01n/a2
Sep ’25n/a
US$4.12
0%
2.6%US$4.23US$4.01n/a2
Aug ’25US$2.75
US$4.61
+67.8%
2.9%US$4.75US$4.48n/a2
Jul ’25US$3.00
US$4.61
+53.8%
2.9%US$4.75US$4.48n/a2
Jun ’25US$3.34
US$4.61
+38.3%
2.9%US$4.75US$4.48n/a2
May ’25US$4.46
US$4.60
+3.2%
4.9%US$4.83US$4.38n/a2
Apr ’25n/a
US$4.60
0%
4.9%US$4.83US$4.38n/a2
Mar ’25US$4.26
US$4.60
+8.0%
4.9%US$4.83US$4.38n/a2
Feb ’25n/a
US$3.05
0%
18.3%US$3.60US$2.49n/a2
Jan ’25US$4.25
US$3.05
-28.3%
18.3%US$3.60US$2.49n/a2
Dec ’24US$3.27
US$2.58
-21.2%
2.6%US$2.64US$2.51n/a2
Nov ’24US$2.22
US$2.23
+0.2%
8.6%US$2.42US$2.03US$3.002
Oct ’24n/a
US$2.07
0%
17.3%US$2.42US$1.71n/a2
Sep ’24n/a
US$2.75
0%
7.7%US$2.96US$2.54n/a2
Aug ’24n/a
US$2.75
0%
7.7%US$2.96US$2.54US$2.752
Jul ’24n/a
US$2.75
0%
7.7%US$2.96US$2.54US$3.002
Jun ’24US$2.37
US$2.76
+16.4%
7.7%US$2.97US$2.55US$3.342
May ’24US$2.60
US$2.48
-4.7%
4.1%US$2.58US$2.38US$4.462
Apr ’24US$2.55
US$2.72
+6.8%
13.8%US$3.24US$2.36n/a3
Mar ’24US$2.05
US$2.72
+32.9%
13.8%US$3.24US$2.36US$4.263
Feb ’24US$2.57
US$3.70
+43.9%
30.5%US$5.26US$2.12n/a4
Jan ’24US$2.50
US$3.74
+49.5%
27.8%US$5.03US$2.31US$4.254
Dec ’23US$3.40
US$5.06
+48.7%
31.6%US$7.60US$3.26US$3.274
Nov ’23US$3.94
US$5.23
+32.7%
32.3%US$7.19US$3.08US$2.224

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

2.5%

1Y

15.9%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

5.6%

1Y

-4.2%